D6900C00003: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)
Principal Investigator
Pfaendler, Krista
Phase
III (Cancer Control)
Age Group
Adult
Applicable Disease Sites
Gynecologic Cancers
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Jill Stone, LPN
Research Specialist
Phone: +1 304-634-4417
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.